JP2005524399A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524399A5
JP2005524399A5 JP2004501579A JP2004501579A JP2005524399A5 JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5 JP 2004501579 A JP2004501579 A JP 2004501579A JP 2004501579 A JP2004501579 A JP 2004501579A JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5
Authority
JP
Japan
Prior art keywords
cancer cells
alcam
pharmaceutical composition
ability
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004501579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/014025 external-priority patent/WO2003093443A2/en
Publication of JP2005524399A publication Critical patent/JP2005524399A/ja
Publication of JP2005524399A5 publication Critical patent/JP2005524399A5/ja
Withdrawn legal-status Critical Current

Links

JP2004501579A 2002-05-03 2003-05-02 Ａｌｃａｍおよびａｌｃａｍ調節因子 Withdrawn JP2005524399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37747902P 2002-05-03 2002-05-03
PCT/US2003/014025 WO2003093443A2 (en) 2002-05-03 2003-05-02 Alcam and alcam modulators

Publications (2)

Publication Number Publication Date
JP2005524399A JP2005524399A (ja) 2005-08-18
JP2005524399A5 true JP2005524399A5 (enExample) 2006-03-16

Family

ID=29401505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501579A Withdrawn JP2005524399A (ja) 2002-05-03 2003-05-02 Ａｌｃａｍおよびａｌｃａｍ調節因子

Country Status (7)

Country Link
US (1) US20040048319A1 (enExample)
EP (1) EP1501544A4 (enExample)
JP (1) JP2005524399A (enExample)
CN (1) CN1662254A (enExample)
AU (1) AU2003225294A1 (enExample)
CA (1) CA2483912A1 (enExample)
WO (1) WO2003093443A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287163A1 (en) * 2004-05-17 2007-12-13 Crucell Holland B.V. Methods for Diagnosis of Acute Myeloid Leukemia
US7674619B2 (en) 2005-02-02 2010-03-09 Mather Jennie P ADAM-9 modulators
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product
US20100216652A1 (en) * 2007-04-25 2010-08-26 The Trustees Of The Universit Of Pennsylvania Low Level Fluorescence Detection at the Light Microscopic Level
EP2065399A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
WO2009059393A1 (en) * 2007-11-06 2009-05-14 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient sample
EP2215251A2 (en) 2007-11-30 2010-08-11 Siemens Healthcare Diagnostics GmbH Method for predicting therapy responsiveness in basal like tumors
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
SG168430A1 (en) * 2009-07-22 2011-02-28 Agency Science Tech & Res Molecular signature of human lung cancer initiating cells
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
KR101213445B1 (ko) 2011-01-13 2012-12-18 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
WO2013033734A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
WO2014059372A1 (en) * 2012-10-11 2014-04-17 Vanderbilt University Characterization of cancer using detection of activated leukocyte cell adhesion molecule (alcam) shedding
WO2015171736A2 (en) * 2014-05-07 2015-11-12 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
JP7028648B2 (ja) 2015-05-04 2022-03-02 サイトメックス セラピューティクス インコーポレイテッド 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法
US10765742B2 (en) 2015-07-17 2020-09-08 The Trustees Of Columbia University In The City Of New York Methods of treating CD166-expressing cancer
SI3328419T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3652210A1 (en) 2017-07-14 2020-05-20 CytomX Therapeutics, Inc. Anti-cd166 antibodies and uses thereof
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
EP3861027A4 (en) * 2018-10-05 2022-09-28 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5846535A (en) * 1990-10-12 1998-12-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0726912A4 (en) * 1993-11-02 2000-08-23 Univ Duke Cd6 ligand
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5968768A (en) * 1993-11-02 1999-10-19 Duke University CD6 ligand encoding sequence
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Similar Documents

Publication Publication Date Title
JP2005524399A5 (enExample)
JP5109031B2 (ja) 細胞結合性ｃａ１２５／ｏ７７２ｐに結合する抗体およびその使用方法
Dohlsten et al. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
CN113924103B (zh) 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
JP2019107018A5 (enExample)
JP2008529497A5 (enExample)
US9657066B2 (en) Pseudomonas exotoxin A with less immunogenic B cell epitopes
JP2020524174A5 (enExample)
UA104130C2 (uk) Антитіло, що специфічно зв'язується з il-4 і іl-13 та спосіб лікування астми у ссавця за допомогою такого антитіла
JP2007504280A5 (enExample)
JP2010508847A5 (enExample)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
RU2183215C2 (ru) Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
JP2005505256A5 (enExample)
CN102027014A (zh) 用于治疗癌症的新抗体
WO2011137687A1 (zh) 一种抗癌胚抗原抗体及其应用
EP4130046A1 (en) Platform for constructing multispecific antibody
CN117482261A (zh) 放射性免疫缀合物与检查点抑制剂组合疗法
TWI726217B (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
CN116887861A (zh) 靶向cd147的抗体
CN111825766B (zh) 抗il-4r单域抗体及其应用
EP3313871A1 (en) Proteins comprising a mutated lair-1 fragment and uses thereof
CN110139661A (zh) Igfb3及其受体相关疾病的治疗
Zhu et al. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
CN1946740B (zh) 抗人腱生蛋白单克隆抗体